Abstract: A device for defibrillation and monitoring, a monitoring component, and a component for defibrillation and monitoring, are disclosed. The device for defibrillation and monitoring includes a host and a monitoring apparatus, which are assembled and disassembled through a detachably connection. The host is capable of independently performing defibrillation operations and display defibrillation information at least. Therefore, when it is necessary to go out for defibrillation operation alone, only the host is carried to medical assistance facilities. This monitoring apparatus can independently implement monitoring functions. When it is necessary to go out for implementing separate monitoring operations, just the monitoring apparatus is carried to the medical assistance facilities. Therefore, the user flexibly selects the devices they carry according to their requirements, improving the convenience of use.

Abstract: The present disclosure provides an Alcaligenes faecalis strain capable of degrading ethylene oxide and uses thereof. The deposit number of the strain is CGMCC No. 18435. This strain can be used in pollution treatment, for example, to treat industrial sewage or wastewater containing ethylene oxide, which greatly improves the decontamination ability of ethylene oxide in manufacturing industries. The present disclosure also provides a degradation agent for degrading ethylene oxide and a method for biodegrading ethylene oxide.

Abstract: The present disclosure discloses a method for screening bacteria capable of tolerating and degrading ethylene oxide, comprising: preliminary screening, purification, ethylene oxide tolerance acclimatization, and ethylene oxide degradation acclimatization. The methods for screening and acclimatization provided by the present application is simple to operate, and the ability of the acclimatized strains to degrade ethylene oxide is significantly improved. Therefore, a series of ethylene oxide-degrading strains capable of tolerating and degrading ethylene oxide may be obtained, which have excellent treatment performance and is safe, environmentally friendly, and is of great significance for decontamination treatment of ethylene oxide.

Abstract: The present disclosure provides an Alcaligenes faecalis strain capable of degrading ethylene oxide and uses thereof. The deposit number of the strain is CGMCC No. 18435. This strain can be used in pollution treatment, for example, to treat industrial sewage or wastewater containing ethylene oxide, which greatly improves the decontamination ability of ethylene oxide in manufacturing industries. The present disclosure also provides a degradation agent for degrading ethylene oxide and a method for biodegrading ethylene oxide.

Abstract: The present disclosure discloses a method for screening bacteria capable of tolerating and degrading ethylene oxide, comprising: preliminary screening, purification, ethylene oxide tolerance acclimatization, and ethylene oxide degradation acclimatization. The methods for screening and acclimatization provided by the present application is simple to operate, and the ability of the acclimatized strains to degrade ethylene oxide is significantly improved. Therefore, a series of ethylene oxide-degrading strains capable of tolerating and degrading ethylene oxide may be obtained, which have excellent treatment performance and is safe, environmentally friendly, and is of great significance for decontamination treatment of ethylene oxide.

Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.

Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.